• Doxycycline as a Precision Tool for 3D Cell Mechanotransduct

  2026-05-26

  Explore how Doxycycline, a tetracycline antibiotic, enables advanced mechanotransduction studies in three-dimensional hydrogel models. This in-depth review connects antiproliferative and metalloproteinase-inhibitory properties to the latest stem cell differentiation assays, offering unique insights for cancer research and tissue engineering.

• Thiothixene: Typical Antipsychotic Agent for Efferocytosis E

  2026-05-26

  Thiothixene is a typical antipsychotic agent that not only targets central dopamine D2 and serotonin 5-HT2A receptors but also enhances macrophage efferocytosis via the vitamin A signaling pathway. This dual mechanism underlies its established role in schizophrenia therapy and its emerging applications in immunological research. Recent evidence demonstrates its ability to induce Arginase 1 and Stra6l, promoting continual efferocytosis in vitro and in vivo.

• HDAC Inhibition Disrupts NUT Carcinoma Oncogenic Transcripti

  2026-05-25

  Shiota et al. identified structurally diverse histone deacetylase (HDAC) inhibitors as potent repressors of NUT function in NUT carcinoma, using a high-throughput chemical screen. Their findings define a mechanistic link between HDAC inhibition and disruption of BRD4-NUT-driven oncogenic transcription, suggesting therapeutic potential for this aggressive cancer.

• Angiotensin (1-7): Applied Protocols and Troubleshooting Ins

  2026-05-25

  Angiotensin (1-7), the Mas receptor agonist, offers multi-system research advantages as an anti-fibrotic and anti-inflammatory agent. This article delivers practical, data-driven guidance for experimental design, protocol optimization, and troubleshooting with APExBIO's high-purity Angiotensin (1-7), including actionable workflow enhancements inspired by recent mechanistic breakthroughs.

• Paroxetine Mesylate: Mechanisms, Targets, and Research Appli

  2026-05-24

  Paroxetine Mesylate is a selective serotonin reuptake inhibitor with multi-target kinase and cytochrome P450 inhibitory activity. It serves as both a clinical antidepressant and a versatile research tool in oncology, neurology, and kinase biology. Evidence supports its molecular actions on SERT, CYP2D6, GRK2, MET, and ERBB3.

• Dihydrotestosterone: Precision Tools Against Anti-Androgen R

  2026-05-23

  This article explores how Dihydrotestosterone (DHT) enables translational researchers to dissect androgen receptor and EGFR/ERBB2 signaling, providing mechanistic and strategic insight into overcoming anti-androgen resistance in advanced prostate cancer. We blend biological rationale, experimental protocols, and competitive context, connecting recent discoveries—such as ECM1-driven MAPK activation—with actionable guidance for bridging preclinical models to future therapies.

• Zosuquidar (LY335979) in Multidrug Resistance Research: Appl

  2026-05-22

  Zosuquidar (LY335979) 3HCl from APExBIO empowers researchers to reverse multidrug resistance (MDR) in cancer models with high precision. This article delivers actionable protocols, troubleshooting wisdom, and practical insights for leveraging this potent P-glycoprotein inhibitor in both in vitro and in vivo contexts.

• ARCA Cy5 EGFP mRNA (5-moUTP): Precision in mRNA Delivery Ass

  2026-05-22

  ARCA Cy5 EGFP mRNA (5-moUTP) empowers researchers to visualize, quantify, and optimize mRNA delivery and translation in mammalian cells with unmatched fluorescence fidelity and immune-evasive stability. Its dual-labeling and 5-methoxyuridine modification streamline workflows for localization and efficiency assays, distinguishing it as a gold-standard control in both fundamental and translational mRNA research.

• PPM-18: Precision iNOS Expression Inhibition via NF-κB Block

  2026-05-21

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) is a potent, selective inhibitor of inducible nitric oxide synthase (iNOS) expression. It acts by blocking NF-κB from binding the iNOS promoter, resulting in robust anti-inflammatory effects. This detailed dossier summarizes its mechanism, evidence, and optimized research applications.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Protocol

  2026-05-21

  The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) is designed to prevent protein degradation during extraction, especially for workflows requiring mass spectrometry compatibility. It is not suitable for metalloproteinase inhibition unless supplemented with EDTA. Use this product for robust protection against serine, cysteine, acid proteases, and aminopeptidases, but avoid in workflows mandating AEBSF.

• 2-NBDG Fluorescent Glucose Uptake Assays: Advanced Workflows

  2026-05-20

  2-NBDG enables rapid, quantitative glucose uptake analysis in live cells and tissues, empowering researchers to profile metabolic dynamics with exceptional sensitivity. This article translates recent breakthroughs and troubleshooting strategies into actionable protocols for diabetes and metabolism research.

• ICG001: Advancing Wnt/β-Catenin Pathway Inhibition in Fibros

  2026-05-20

  Explore how ICG001, a selective Wnt/β-catenin pathway inhibitor, enables mechanistic dissection of fibrosis progression and EMT in disease models. This article uniquely examines protocol optimization and translational considerations for leveraging ICG001 in advanced research applications.

• MitMAB in Organoid Research: Redefining Endocytosis Assays

  2026-05-19

  Explore the advanced role of MitMAB in dissecting endocytosis mechanisms within intestinal organoid models. This article delivers a deep scientific analysis and practical guidance for researchers seeking precise control over dynamin-dependent membrane trafficking.

• Digestive Metabolomics of Withania somnifera: Implications f

  2026-05-19

  This study pioneers a detailed metabolomic analysis of Withania somnifera (ashwagandha) extracts under simulated digestive conditions, revealing compound-specific stability and transformation. The findings refine in vitro modeling approaches for botanical mixtures, enhancing translational relevance for research on bioactive natural products.

• Asunaprevir (BMS-650032): Optimizing HCV RNA Replication Inh

  2026-05-18

  Asunaprevir (BMS-650032) empowers researchers with broad-spectrum, nanomolar HCV NS3 protease inhibition and robust performance in complex cell models. This guide details advanced workflows, cross-platform troubleshooting, and actionable insights for maximizing assay reliability in hepatitis C research.

454 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page